800-845-6913
Tuteur Law Networks | Knowledge is Power.
January 25, 2007
Leverkusen, Germany and West Haven, Connecticut, January 25, 2007 – Bayer HealthCare has decided to end three ongoing clinical studies investigating the safety and efficacy of Trasylol® (aprotinin injection) on transfusion requirements and blood loss in adults undergoing: elective spinal fusion surgery, pneumonectomy or esophagectomy for cancer, and radical or total cystectomy in bladder cancer. Continue reading, ‘01-25-2007 | Bayer Pharmaceuticals Trasylol® (aprotinin injection) Press Release.’